| Drug ID: | Drug39 |
|---|---|
| Drug Name: | Thalidomide |
| CID: | 5426 |
| DrugBank ID: | DB01041 |
| Modality: | Small Molecule |
| Groups: | approved|investigational|withdrawn |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06382519, , NCT00720538 |
| Molecular Formula: | C13H10N2O4 |
| Molecular Weight: | 258.23 g/mol |
| Isomeric SMILES: | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
| Synonyms: | thalidomide; 50-35-1; Contergan; Distaval; Pantosediv; Softenon; Kevadon; Theophilcholine; Algosediv; Corronarobetin |
| Phase 0: | 2 |
| Phase 1: | 33 |
| Phase 2: | 265 |
| Phase 3: | 97 |
| Phase 4: | 20 |
| Description: | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt355 | 5426 | Thalidomide | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt356 | 5426 | Thalidomide | 2263 | FGFR2 | Homo sapiens (human) | None | |
| dt357 | 5426 | Thalidomide | 7124 | TNF | Homo sapiens (human) | None | |
| dt358 | 5426 | Thalidomide | 8451 | CUL4A | Homo sapiens (human) | Inhibitor | |
| dt359 | 5426 | Thalidomide | 51185 | CRBN | Homo sapiens (human) | 20223979 | Binding |
| dt360 | 5426 | Thalidomide | 2651 | GCNT2 | Mus musculus (house mouse) | 26217789 | Thalidomide results in decreased expression of GCNT2 mRNA |
| dt361 | 5426 | Thalidomide | 2638 | GC | Gallus gallus (chicken) | 28892372 | Thalidomide results in decreased expression of GC mRNA |
| dt362 | 5426 | Thalidomide | 6241 | RRM2 | Homo sapiens (human) | 18720364 | [azacitidine co-treated with thalidomide] affects the expression of RRM2 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06382519 | Thalidomide Therapy for VEOIBD | None | RECRUITING | Children's Hospital of Fudan University | Inflammatory Bowel Diseases | DRUG: Thalidomide | Details |
| NCT00720538 | Thalidomide in Pediatric Inflammatory Bowel Diseases. | PHASE3 | COMPLETED | IRCCS Burlo Garofolo | Inflammatory Bowel Diseases|Crohn's Disease|Ulcer… | DRUG: Thalidomide|DRUG: placebo | Details |
| ISRCTN23541842 | The auxiliary diagnostic value of fissured tongue on axial and peripheral joint dysfunction in Ankylosing Spondylitis | Not Available | Not Recruiting | Zhejiang University Of Chinese Medicine | Ankylosing spondylitis Musculoskeletal Diseases … | Participants are screened and undergo a clinical … | Details |
| EUCTR2005-005414-20-IT | Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis. - Thalidomide and IBD | Not Available | Authorised | ISTITUTO PER L INFANZIA BURLO GAROFOLO | Inflammatory Bowel Disease Crohn Disease, Ulcera… | Trade Name: Thalidomide Pharmion Pharmaceutical F… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Thalidomide for inflammatory bowel disease: Systematic review
PMID: 27472695
Year: 2016
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Thalidomide is an immunomodulatory drug used in the experimental treatment of refractory Crohn disease and ulcerative colitis. We aimed t…
Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ul…
PMID: 26185909
Year: 2015
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: In a randomized controlled trial, thalidomide has shown to be effective in refractory Crohn's disease in children. This pilot study aimed…
Thalidomide as rescue therapy for acute severe ulcerative colitis
PMID: 24992607
Year: 2014
Relationship Type:
Treatment
Score: 6.3
INTRODUCTION: Acute severe exacerbations of Ulcerative Colitis (UC) represent a medical emergency in children and adults. Intravenous steroids remain…
Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young r…
PMID: 24931258
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Thalidomide could relieve clinical symptoms and intestinal mucosal lesions effectively in children with refractory inflammatory bowel dis…
[An analysis of adverse drug reactions of thalidomide in treatment of immune-re…
PMID: 24314159
Year: 2013
Relationship Type:
Treatment
Score: 6.1
OBJECTIVE: To investigate the safety of thalidomide in the treatment of immune-related bowel diseases for providing clinical reference. METHODS: Thir…
Effect of thalidomide on clinical remission in children and adolescents with re…
PMID: 24281461
Year: 2013
Relationship Type:
Treatment
Score: 6.1
IMPORTANCE: Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead t…
Idiopathic ileocolitis with perforation associated with HIV infection: thalidom…
PMID: 23155107
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Idiopathic cutaneous ulcers, oesophageal ulcers and severe ulcerative ileocolitis occurred in a human immunodeficiency virus (HIV)-infected patient e…
Thalidomide induces mucosal healing in Crohn's disease: case report
PMID: 22174554
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that is defined by relapsing and remitting episodes. Tumor necrosis …
Effect of combination of thalidomide and sulfasalazine in experimentally induce…
PMID: 21941940
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Thalidomide provided significant protection against tri nitro benzene sulfonic acid induced colitis. Combination therapy also reduced colonic inflamm…
Thalidomide use and outcomes in pediatric patients with Crohn disease refractor…
PMID: 21681114
Year: 2012
Relationship Type:
Treatment
Score: 6.1
OBJECTIVE: The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who fa…
Treatment of pediatric refractory Crohn's disease with thalidomide
PMID: 21455327
Year: 2011
Relationship Type:
Treatment
Score: 6.1
AIM: To assess the efficacy and tolerability of thalidomide in pediatric Crohn's disease (CD). METHODS: Six patients with refractory CD received thal…
[Thalidomide as immunomodulatory drug: pharmacological actions and its indicati…
PMID: 21048383
Year: 2010
Relationship Type:
Treatment
Score: 6.1
Thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an i…
Thalidomide inhibits inflammatory and angiogenic activation of human intestinal…
PMID: 19926820
Year: 2010
Relationship Type:
Treatment
Score: 6.1
Comment in Dig Liver Dis. 2005 Jun;37(6):391-3. INTRODUCTION: Despite the explosion of biological therapies, the old immunosuppressants continu…